Why Bausch Health Companies Stock Skyrocketed by Almost 40% Last Month

Axe Cap view

Bausch Health’s Surge Offers a Lens on Pharma Momentum

Strong Canadian drug approval and earnings boost Bausch Health but South African investors should look closer at domestic pharma dynamics.

Bausch Health’s near 40% jump last month is impressive, underpinned by a key regulatory win in Canada and a solid earnings beat in Q2. Their Prokedi approval for schizophrenia and raised guidance signal operational strength. However, Bausch isn't listed on the JSE, so South African investors need a local gauge. The domestic pharma space is more constrained, with companies like Aspen or Adcock facing tougher growth and regulatory headwinds. Meanwhile, global pharma volatility tends to reflect in the rand, shaping how foreign earnings impact local portfolios. BHC’s momentum might temporarily lift risk appetite, helping the rand gain against the dollar, though this is short-lived if local fundamentals falter. For South African investors watching the USD/ZAR currency pair, these global moves offer indirect cues but no direct calls on local stocks. The view could be wrong if global pharma growth stalls or regulatory setbacks hit big players, softening the rand and local market sentiment. this is just our opinion and not financial advice